5-(4-tert-butyl-cyclohexyloxymethyl)-4,5-dihydro-oxazol-2-ylamine | 1058158-92-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 亚胺内酰胺
• 英文名称: 5-(4-tert-butyl-cyclohexyloxymethyl)-4,5-dihydro-oxazol-2-ylamine
• 英文别名: 5-[(4-Tert-butylcyclohexyl)oxymethyl]-4,5-dihydro-1,3-oxazol-2-amine
• CAS: 1058158-92-1
• 化学式: C₁₄H₂₆N₂O₂
• 分子量: 254.373
• InChiKey: JMNWZWPQUZYJHC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.93
• 拓扑面积：
  56.8
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF
  申请人：CAO Bin

  公开号：US20100075994A1

  公开（公告）日：2010-03-25

  The present invention relates to a series of substituted dihydro and tetrahydro oxazolopyrimidinones, specifically, to a series of 2-substituted-2,3-dihydro-oxazolo[3,2-a]pyrimidin-7-ones and 2-substituted-2,3,5,6-tetra-hydro-oxazolo[3,2-a]pyrimidin-7-ones of formula (I): Wherein p, n, X, Y, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are as defined herein. This invention also relates to methods of making these compounds including novel intermediates. The compounds of this invention are modulators of metabotropic glutamate receptors (mGluR), particularly, mGluR2 receptor. Therefore, the compounds of this invention are useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of central nervous system disorders (CNS), including but not limited to acute and chronic neurodegenerative conditions, psychoses, convulsions, anxiety, depression, migraine, pain, sleep disorders and emesis.

  本发明涉及一系列取代二氢和四氢噁唑嘧啶酮，具体地说，涉及一系列式(I)的2-取代-2,3-二氢-噁唑并[3,2-a]嘧啶-7-酮和2-取代-2,3,5,6-四氢-噁唑并[3,2-a]嘧啶-7-酮： 其中p、n、X、Y、R1、R2、R3、R4、R5、R6、R7和R8如本文所定义。本发明还涉及制备这些化合物的方法，包括新颖的中间体。本发明的化合物是代谢型谷氨酸受体（mGluR）的调节剂，特别是mGluR2受体。因此，本发明的化合物在药物制剂中具有用途，特别是在治疗和/或预防各种中枢神经系统疾病（CNS）方面，包括但不限于急性和慢性神经退行性疾病、精神病、癫痫、焦虑、抑郁、偏头痛、疼痛、睡眠障碍和呕吐。
• US8642603B2
  申请人：——

  公开号：US8642603B2

  公开（公告）日：2014-02-04
• [EN] SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF<br/>[FR] DIHYDRO ET TÉTRAHYDRO OXAZOLOPYRIMIDINONES SUBSTITUÉES, PRÉPARATION ET UTILISATION DE CELLES-CI
  申请人：SANOFI AVENTIS

  公开号：WO2008112483A2

  公开（公告）日：2008-09-18

  [EN] The present invention relates to a series of substituted dihydro and tetrahydro oxazolopyrimidinones, specifically, to a series of 2-substituted-2,3-dihydro-oxazolo[3,2-a]pyrimidin-7-ones and 2-substituted-2,3,5,6-tetra-hydro-oxazolo[3,2-a]pyrimidin-7-ones of formula (I): Wherein p, n, X, Y, R₁, R₂, R₃, R₄, R₅, R₆, R₇ and R₈ are as defined herein. This invention also relates to methods of making these compounds including novel intermediates. The compounds of this invention are modulators of metabotropic glutamate receptors (mGluR), particularly, mGluR2 receptor. Therefore, the compounds of this invention are useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of central nervous system disorders (CNS), including but not limited to acute and chronic neurodegenerative conditions, psychoses, convulsions, anxiety, depression, migraine, pain, sleep disorders and emesis.
  [FR] La présente invention concerne une série de dihydro et tétrahydro oxazolopyrimidinones substituées, spécifiquement, une série de 2,3-dihydro-oxazolo[3,2-a]pyrimidin-7-ones 2-substituées et de 2,3,5,6-tétra-hydro-oxazolo[3,2-a]pyrimidin-7-ones 2-substituées de formule (I) : dans laquelle p, n, X, Y, R₁, R₂, R₃, R₄, R₅, R₆, R₇ et R₈ sont tels que définis dans le présent document. L'invention concerne également des procédés de fabrication de ces composés y compris de nouveaux intermédiaires. Les composés de cette invention sont des modulateurs des récepteurs métabotropiques du glutamate (mGluR), particulièrement, du récepteur mGluR2.